Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer Clinical Trial

Official title:

An Open-Label, Multi-Center Phase II Study of Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Patients With Extensive-Stage Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05509699
• Other study ID #: 2022-012-00CH1
• Status: Recruiting
• Phase: Phase 2
• Start date: September 27, 2022
• Est. completion date: December 2024

Study information

• Verified date: March 2023
• Source: Hutchmed
• Contact: Hannah Yang, Master
• Phone: 86 21 2067 1962
• Email: hannahy[@]hutch-med.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multi-center Phase II study designed to evaluate the efficacy and safety of Surufatinib plus anti-PD-1/L1 as maintenance therapy after first-line standard of care in patients with ES-SCLC.

Description:

This study consists of two parts, i.e., a single-arm Phase IIa study and a randomized, controlled Phase IIb study. All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after prior platinum-based chemotherapy in combination with an anti-PD-1/L1. Approximately 20 patients are planned to be enrolled in the single-arm Phase IIa study to preliminarily observe the efficacy and safety. Approximately 40 patients are planned to be enrolled in the randomized and controlled Phase IIb study with 20 patients per group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients who sufficiently understand this study and is willing to sign the ICF;

2. Aged from 18 to 75 years (inclusive);

3. Patients with histologically or cytologically confirmed ES-SCLC ;

4. Patients who did not have PD (assessed as per the RECIST v1.1) after prior first-line platinum-based chemotherapy plus an anti-PD-1/L1;

5. Patients with measurable lesions as defined in the RECIST v1.1 ;

6. Life expectancy = 12 weeks;

7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1;

8. Adequate organ function:

9. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose. Male or female patients of childbearing potential should be willing to use effective contraceptive methods during the study and within 90 days after last dose of the study drug.

Exclusion Criteria:

1. Previous use of anti-vascular endothelial growth factor (VEGF) drugs/anti-vascular endothelial growth factor receptor (VEGFR) agents;

2. Use of systematic anti-tumor therapies other than first-line platinum-based chemotherapy in combination with anti-PD-1/L1 within 4 weeks prior to the first dose;

3. Presence of central nervous system (CNS) metastasis and/or cancerous meningitis (metastases to meninges);

4. Toxicities associated with previous anti-tumor treatment that has not been resolved to CTCAE Grade = 1, except for alopecia and CTCAE Grade = 2 peripheral neurotoxicity;

5. Uncontrollable malignant hydrothorax, ascites or pericardial effusion;

6. Patients with active autoimmune disorder or immunodeficiency or history of autoimmune disorder or immunodeficiency;

7. Patients with evidence or history of obvious bleeding tendency within 2 months prior to the first dose;

8. Clinically significant cardiovascular disorders;

9. Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteraemia or severe pneumonia;

10. Patients who are unable to take oral medications, or with previous surgical history or severe gastrointestinal;

11. Pregnant (with a positive pregnancy test) or lactating women within 5 years before screening.

12. Patients with a history of malignant tumors excluding small cell lung cancer (SCLC) within 5 years before screening.

Related Conditions & MeSH terms

• Extensive-Stage Small Cell Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Drug:
• Surufatinib
The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
• Anti-PD-1/L1
Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	Progression-free survival(PFS) assessed by the investigator as per the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)	About 18 months
Secondary	Overall survival	Overall survival (OS)	About 18 months
Secondary	Objective response rate	Objective response rate (ORR) assessed per RECIST v1.1	About 18 months
Secondary	Disease control rate	Disease control rate (DCR) assessed per RECIST v1.1	About 18 months
Secondary	Duration of response	Duration of response (DoR) assessed per RECIST v1.1	About 18 months